Keywords
Last Name
Institution

FREDRICK B HAGEMEISTER

TitleProfessor
InstitutionMD Anderson
DepartmentLymphoma-Myeloma
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. 2016 Jul; 27(7):1317-23. PMID: 27091808.
      View in: PubMed
    2. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. 2016 May; 27(5):895-901. PMID: 26802151.
      View in: PubMed
    3. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):122-8. PMID: 26795083.
      View in: PubMed
    4. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016 Jan; 172(1):80-8. PMID: 26648336.
      View in: PubMed
    5. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. 2015 Dec; 171(5):726-35. PMID: 26358140.
      View in: PubMed
    6. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015 Nov; 171(4):509-16. PMID: 26260306.
      View in: PubMed
    7. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015 May 1; 92(1):175-82. PMID: 25863764.
      View in: PubMed
    8. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 1; 92(1):113-21. PMID: 25863759.
      View in: PubMed
    9. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol. 2015 Jun; 169(6):814-23. PMID: 25828695.
      View in: PubMed
    10. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 2015 Jul; 100(7):e272-4. PMID: 25820332.
      View in: PubMed
    11. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015 Jun; 26(6):1175-9. PMID: 25712454.
      View in: PubMed
    12. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8. PMID: 25439689.
      View in: PubMed
    13. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):152-8. PMID: 25445468; PMCID: PMC4344896.
    14. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2014 Oct; 167(2):177-84. PMID: 25039868.
      View in: PubMed
    15. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901. PMID: 24943107.
      View in: PubMed
    16. Dabaja BS, Hess K, Shihadeh F, Podoloff DA, Medeiros LJ, Mawlawi O, Arzu I, Oki Y, Hagemeister FB, Fayad LE, Reed VK, Kedir A, Wogan CF, Rodriguez A. Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation. Int J Radiat Oncol Biol Phys. 2014 Jun 1; 89(2):384-91. PMID: 24721592.
      View in: PubMed
    17. Thompson MA, Westin JR, Hagemeister FB. Bone mineral density screening should be routine in lymphoma patients. Ann Oncol. 2014 Apr; 25(4):913-4. PMID: 24667725.
      View in: PubMed
    18. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol. 2014 Apr; 165(1):112-6. PMID: 24386943.
      View in: PubMed
    19. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan; 15(1):69-77. PMID: 24332512.
      View in: PubMed
    20. Westin J, Hagemeister F. R-CHOP every 21 days for diffuse large B-cell lymphoma: still the standard of care? J Comp Eff Res. 2013 Nov; 2(6):537-40. PMID: 24236792.
      View in: PubMed
    21. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013 Dec 15; 19(24):6882-90. PMID: 24097867; PMCID: PMC4409814.
    22. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20. PMID: 24117234.
      View in: PubMed
    23. Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, Samaniego F, Silverman JA, Sarris A, Cabanillas F. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol. 2013 Sep; 162(5):631-8. PMID: 23802738.
      View in: PubMed
    24. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Dec; 54(12):2631-8. PMID: 23488661; PMCID: PMC3827734.
    25. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2013 Jul; 162(1):138-41. PMID: 23590726.
      View in: PubMed
    26. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep; 27(9):1902-9. PMID: 23545991.
      View in: PubMed
    27. Churpek JE, Pro B, van Besien K, Kline J, Conner K, Wade JL, Hagemeister F, Karrison T, Smith SM. A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. Cancer. 2013 May 1; 119(9):1683-9. PMID: 23310949.
      View in: PubMed
    28. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):99-105. PMID: 23276888.
      View in: PubMed
    29. Hagemeister FB. 'Watch and wait' as initial management for patients with follicular lymphomas: still a viable strategy? BioDrugs. 2012 Dec 1; 26(6):363-76. PMID: 23057946.
      View in: PubMed
    30. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):15-8. PMID: 23137719.
      View in: PubMed
    31. Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 2012 Nov 20; 30(33):4161-7. PMID: 22965964.
      View in: PubMed
    32. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, Lambert JM, Morariu-Zamfir R, Payrard S, Gordon LI. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol. 2012 Aug 1; 30(22):2776-82. PMID: 22753910.
      View in: PubMed
    33. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul; 13(7):716-23. PMID: 22677155.
      View in: PubMed
    34. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood. 2012 Mar 1; 119(9):2171-2. PMID: 22383790.
      View in: PubMed
    35. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 3; 119(18):4123-8. PMID: 22371887; PMCID: PMC3359733.
    36. Batty N, Hagemeister FB, Feng L, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study. Leuk Lymphoma. 2012 May; 53(5):801-6. PMID: 22023528.
      View in: PubMed
    37. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma. 2012 Jan; 53(1):50-6. PMID: 21895545; PMCID: PMC4104165.
    38. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5. PMID: 22015451; PMCID: PMC4110463.
    39. Thomas DA, O'Brien S, Faderl S, Manning JT, Romaguera J, Fayad L, Hagemeister F, Medeiros J, Cortes J, Kantarjian H. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases? Curr Hematol Malig Rep. 2011 Mar; 6(1):58-66. PMID: 21191675.
      View in: PubMed
    40. Hagemeister FB. Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data. Curr Oncol Rep. 2010 Nov; 12(6):395-401. PMID: 20820960.
      View in: PubMed
    41. Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, Gladish G, Vadhan-Raj S. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med. 2010 Oct; 123(10):935-41. PMID: 20920696.
      View in: PubMed
    42. Morris GJ, Dotan E, Smith MR, Hagemeister FB, Brereton HD. Gastric mucosa-associated lymphoid tissue lymphoma. Semin Oncol. 2010 Jun; 37(3):183-7. PMID: 20709202.
      View in: PubMed
    43. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010 Jul; 150(2):200-8. PMID: 20528872.
      View in: PubMed
    44. Hagemeister F. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2010 Feb 12; 70(3):261-72. PMID: 20166765.
      View in: PubMed
    45. Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther. 2009 Nov; 9(11):1445-51. PMID: 19817678.
      View in: PubMed
    46. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009 Nov 1; 27(31):5213-8. PMID: 19770379.
      View in: PubMed
    47. Hagemeister F, Manoukian G. Bendamustine in the treatment of non-Hodgkin's lymphomas. Onco Targets Ther. 2009; 2:269-79. PMID: 20616914.
      View in: PubMed
    48. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009 Apr 30; 113(18):4144-52. PMID: 19168784; PMCID: PMC4624445.
    49. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol. 2009 Apr; 20(4):709-14. PMID: 19150940.
      View in: PubMed
    50. Morschhauser F, Dreyling M, Rohatiner A, Hagemeister F, Bischof Delaloye A. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist. 2009; 14 Suppl 2:17-29. PMID: 19819921.
      View in: PubMed
    51. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer. 2008 Nov 15; 113(10):2734-41. PMID: 18973182.
      View in: PubMed
    52. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol. 2008 Nov; 143(3):355-60. PMID: 18764869.
      View in: PubMed
    53. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15; 111(12):5530-6. PMID: 18411419; PMCID: PMC4624452.
    54. Oki Y, Pro B, Fayad LE, Romaguera J, Samaniego F, Hagemeister F, Neelapu S, McLaughlin P, Goy A, Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer. 2008 Feb 15; 112(4):831-6. PMID: 18085611.
      View in: PubMed
    55. Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008 Feb; 93(2):257-64. PMID: 18223284.
      View in: PubMed
    56. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol. 2008 Mar; 19(3):553-9. PMID: 18083690.
      View in: PubMed
    57. Leonard JP, Friedberg JW, Hagemeister FB, Levine AM. Combination treatment approaches and novel therapies for lymphoma. Clin Adv Hematol Oncol. 2007 Aug; 5(8 Suppl 12):4-20; quiz 1 p following 20. PMID: 18154235.
      View in: PubMed
    58. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez AM, Romaguera JE, Hagemeister FB, Pro B. Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature. Am J Hematol. 2007 Aug; 82(8):725-8. PMID: 17373675.
      View in: PubMed
    59. Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Aug; 138(4):502-5. PMID: 17608763.
      View in: PubMed
    60. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer. 2007 Jun 15; 109(12):2481-9. PMID: 17497648.
      View in: PubMed
    61. Hagemeister FB. Hodgkin's lymphoma in younger patients: lessons learned on the road to success. Oncology (Williston Park). 2007 Apr; 21(4):434-40; discussion 441-2, 445-6. PMID: 17474345.
      View in: PubMed
    62. Fayad L, Hagemeister F. Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: newer therapies needed. Leuk Lymphoma. 2007 Apr; 48(4):657-8. PMID: 17454622.
      View in: PubMed
    63. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Feb; 136(3):439-47. PMID: 17233846.
      View in: PubMed
    64. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis. 2006 Nov 15; 194(10):1394-7. PMID: 17054068.
      View in: PubMed
    65. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer. 2006 Sep 15; 107(6):1294-302. PMID: 16902984.
      View in: PubMed
    66. Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Cabanillas F, Tiongson LP, Younes A. Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Sep; 47(9):1818-21. PMID: 17064994.
      View in: PubMed
    67. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 1; 106(7):1569-80. PMID: 16502413.
      View in: PubMed
    68. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006 Apr 1; 24(10):1582-9. PMID: 16575009.
      View in: PubMed
    69. Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Mar; 47(3):481-5. PMID: 16396772.
      View in: PubMed
    70. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005 Oct 1; 23(28):7013-23. PMID: 16145068.
      View in: PubMed
    71. Poonawalla T, Jones D, Hagemeister F, Duvic M. Acral necrotizing mycosis fungoides. Clin Lymphoma Myeloma. 2005 Sep; 6(2):146-8. PMID: 16231855.
      View in: PubMed
    72. Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer. 2005 Aug 15; 104(4):781-7. PMID: 15973667.
      View in: PubMed
    73. Tsimberidou AM, Younes A, Romaguera J, Hagemeister FB, Rodriguez MA, Feng L, Ayala A, Smith TL, Cabanillas F, McLaughlin P. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer. 2005 Jul 15; 104(2):345-53. PMID: 15948158.
      View in: PubMed
    74. Hagemeister FB. Stem-cell transplant for Hodgkin's lymphoma: does choice of therapy prior to high-dose treatment matter? Nat Clin Pract Oncol. 2005 Jul; 2(7):344-5. PMID: 16075792.
      View in: PubMed
    75. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, Hayes K, Maddox AM, Preti HA, Hagemeister FB. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood. 2005 Jun 15; 105(12):4573-5. PMID: 15741224; PMCID: PMC1895007.
    76. Hagemeister F, Cabanillas F, Coleman M, Gregory SA, Zinzani PL. The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist. 2005 Feb; 10(2):150-9. PMID: 15709217.
      View in: PubMed
    77. Romaguera J, Hagemeister FB. Lymphoma of the colon. Curr Opin Gastroenterol. 2005 Jan; 21(1):80-4. PMID: 15687889.
      View in: PubMed
    78. Hagemeister F, Huen A. The status of allopurinol in the management of tumor lysis syndrome: a clinical review. Cancer J. 2005 Jan-Feb; 11 Suppl 1:S1-10. PMID: 15835720.
      View in: PubMed
    79. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005 Feb 1; 23(4):667-75. PMID: 15613697.
      View in: PubMed
    80. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol. 2004 Oct 15; 22(20):4095-102. PMID: 15353540.
      View in: PubMed
    81. Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res. 2004 Aug 15; 10(16):5432-8. PMID: 15328181.
      View in: PubMed
    82. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin RE. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23. PMID: 15048145.
      View in: PubMed
    83. Khoury JD, Jones D, Yared MA, Manning JT, Abruzzo LV, Hagemeister FB, Medeiros LJ. Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol. 2004 Apr; 28(4):489-95. PMID: 15087668.
      View in: PubMed
    84. Pro B, Younes A, Albitar M, Dang NH, Samaniego F, Romaguera J, McLaughlin P, Hagemeister FB, Rodriguez MA, Clemons M, Cabanillas F. Thalidomide for patients with recurrent lymphoma. Cancer. 2004 Mar 15; 100(6):1186-9. PMID: 15022285.
      View in: PubMed
    85. Chronowski GM, Wilder RB, Levy LB, Atkinson EN, Ha CS, Hagemeister FB, Barista I, Rodriguez MA, Sarris AH, Hess MA, Cabanillas F, Cox JD. Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol. 2004 Feb; 27(1):73-80. PMID: 14758137.
      View in: PubMed
    86. Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep. 2003 Sep-Oct; 10(5):1513-8. PMID: 12883733.
      View in: PubMed
    87. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT, Jones D, Abruzzo LV, Medeiros LJ. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003 Jul 15; 98(2):310-4. PMID: 12872350.
      View in: PubMed
    88. Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, Rodriguez MA, Ha CS, Smith TL, Ayala A, Hess M, Cox JD, Cabanillas F, McLaughlin P. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003 Jun 1; 21(11):2115-22. PMID: 12775737.
      View in: PubMed
    89. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003 Feb 1; 97(3):586-91. PMID: 12548600.
      View in: PubMed
    90. Hagemeister FB. Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy. Clin Adv Hematol Oncol. 2003 Feb; 1(2):120-5. PMID: 16224391.
      View in: PubMed
    91. Frias S, Van Hummelen P, Meistrich ML, Lowe XR, Hagemeister FB, Shelby MD, Bishop JB, Wyrobek AJ. NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, and 21. Cancer Res. 2003 Jan 1; 63(1):44-51. PMID: 12517776.
      View in: PubMed
    92. Chronowski GM, Wilder RB, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemeister FB, Barista I, Cabanillas F, Cox JD. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys. 2003 Jan 1; 55(1):36-43. PMID: 12504034.
      View in: PubMed
    93. Hagemeister FB. Mantle cell lymphoma: non-myeloablative versus dose-intensive therapy. Leuk Lymphoma. 2003; 44 Suppl 3:S69-75. PMID: 15202528.
      View in: PubMed
    94. Chronowski GM, Wilder RB, Tucker SL, Ha CS, Sarris AH, Hagemeister FB, Barista I, Hess MA, Cabanillas F, Cox JD. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer. 2002 Dec 15; 95(12):2534-8. PMID: 12467067.
      View in: PubMed
    95. Gibson AD, D'Orazio A. VIII International Conference on malignant lymphoma. June 12-15, 2002 Lugano, Switzerland. Clin Lymphoma. 2002 Sep; 3(2):75-81. PMID: 12435279.
      View in: PubMed
    96. Schlembach PJ, Wilder RB, Jones D, Ha CS, Fayad LE, Younes A, Hagemeister F, Hess M, Cabanillas F, Cox JD. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J. 2002 Sep-Oct; 8(5):377-83. PMID: 12416895.
      View in: PubMed
    97. Tsimberidou AM, McLaughlin P, Younes A, Rodriguez MA, Hagemeister FB, Sarris A, Romaguera J, Hess M, Smith TL, Yang Y, Ayala A, Preti A, Lee MS, Cabanillas F. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood. 2002 Dec 15; 100(13):4351-7. PMID: 12393618.
      View in: PubMed
    98. Sarris AH, Phan A, Goy A, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Medeiros LJ, Samuels B, Mesina O, Bleyer AW, Cabanillas F. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology (Williston Park). 2002 Aug; 16(8 Suppl 7):27-31. PMID: 12199630.
      View in: PubMed
    99. Hagemeister FB. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother Pharmacol. 2002 May; 49 Suppl 1:S13-20. PMID: 12042984.
      View in: PubMed
    100. Wilder RB, Schlembach PJ, Jones D, Chronowski GM, Ha CS, Younes A, Hagemeister FB, Barista I, Cabanillas F, Cox JD. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer. 2002 Mar 15; 94(6):1731-8. PMID: 11920535.
      View in: PubMed
    101. Barista I, Cabanillas F, Romaguera JE, Khouri IF, Yang Y, Smith TL, Strom SS, Medeiros LJ, Hagemeister FB. Is there an increased rate of additional malignancies in patients with mantle cell lymphoma? Ann Oncol. 2002 Feb; 13(2):318-22. PMID: 11886011.
      View in: PubMed
    102. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin RE. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15; 98(13):3595-9. PMID: 11739162.
      View in: PubMed
    103. Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B, Giralt S, Gajewski J, de Lima M, Couriel D, Romaguera J, Cabanillas FF, Champlin RE, Khouri IF. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol. 2001 Sep 1; 19(17):3766-70. PMID: 11533100.
      View in: PubMed
    104. Liao Z, Ha CS, Vlachaki MT, Hagemeister F, Cabanillas F, Hess M, Tucker S, Cox JD. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys. 2001 Jul 15; 50(4):971-7. PMID: 11429225.
      View in: PubMed
    105. Hagemeister FB, Diehl V. The role of ifosfamide in cytoreduction, stem cell mobilization and high-dose therapy in relapsed/refractory malignant lymphomas. Eur J Haematol Suppl. 2001 Jul; 64:1-2. PMID: 11486394.
      View in: PubMed
    106. Hagemeister FB, Donato M. Ifosfamide-based chemotherapy regimens in treatment of lymphoma: the M.D. Anderson experience. Eur J Haematol Suppl. 2001 Jul; 64:8-13. PMID: 11486405.
      View in: PubMed
    107. Younes A, Preti HA, Hagemeister FB, McLaughlin P, Romaguera JE, Rodriguez MA, Samuels BI, Palmer JL, Cabanillas F. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2001 Jul; 12(7):923-7. PMID: 11521796.
      View in: PubMed
    108. Sarris AH, Romaguera J, Hagemeister FB, Rodriguez MA, McLaughlin P, Pro B, Younes A, Mesina O, Cabanillas F, Medeiros LJ, Samuels B. Irinotecan in relapsed or refractory non-Hodgkin's lymphoma. Oncology (Williston Park). 2001 Jul; 15(7 Suppl 8):53-6. PMID: 11497233.
      View in: PubMed
    109. Visco C, Medeiros LJ, Mesina OM, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera JE, Cabanillas F, Sarris AH. Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? Clin Lymphoma. 2001 Jun; 2(1):40-6. PMID: 11707869.
      View in: PubMed
    110. Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeister FB, Romaguera J, Pro B, McLaughlin P, Dang N, Cabanillas F. Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma. 2001 May; 41(5-6):535-44. PMID: 11378571.
      View in: PubMed
    111. Sarris AH, Braunschweig I, Medeiros LJ, Duvic M, Ha CS, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera J, Cox J, Cabanillas F. Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. J Clin Oncol. 2001 Jan 15; 19(2):398-405. PMID: 11208831.
      View in: PubMed
    112. Rodriguez J, McLaughlin P, Fayad L, Santiago M, Hess M, Rodriguez MA, Romaguera J, Hagemeister F, Kantarjian H, Cabanillas F. Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981. Ann Oncol. 2000 Dec; 11(12):1551-6. PMID: 11205462.
      View in: PubMed
    113. Younes A, Cristofanilli M, McLaughlin P, Hagemeister FB, Weber D, Mesina O, Cabanillas F. Experience with 9-cis retinoic acid in patients with relapsed and refractory non-Hodgkin's lymphoma. Leuk Lymphoma. 2000 Dec; 40(1-2):79-85. PMID: 11426631.
      View in: PubMed
    114. McLaughlin P, Hagemeister FB, Rodriguez MA, Sarris AH, Pate O, Younes A, Lee MS, Dang NH, Romaguera JE, Preti AH, McAda N, Cabanillas F. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol. 2000 Dec; 27(6 Suppl 12):37-41. PMID: 11225999.
      View in: PubMed
    115. Sarris AH, Psyrri A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Bachier C, Younes A, Mesina O, Oholendt M, Medeiros LJ, Samuels B, Adams LM, Cabanillas F. Infusional vinorelbine in relapsed or refractory lymphomas. Leuk Lymphoma. 2000 Oct; 39(3-4):291-9. PMID: 11342309.
      View in: PubMed
    116. Romaguera JE, Khouri IF, Kantarjian HM, Hagemeister FB, Rodriguez MA, McLaughlin P, Sarris AH, Younes A, Rodriguez J, Cabanillas F. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000 Sep; 39(1-2):77-85. PMID: 10975386.
      View in: PubMed
    117. Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Körbling MJ, Manning J, Romaguera J, Sarris A. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant. 2000 Sep; 26(6):615-20. PMID: 11041566.
      View in: PubMed
    118. Dubey P, Wilson G, Mathur KK, Hagemeister FB, Fuller LM, Ha CS, Cox JD, Meistrich ML. Recovery of sperm production following radiation therapy for Hodgkin's disease after induction chemotherapy with mitoxantrone, vincristine, vinblastine, and prednisone (NOVP). Int J Radiat Oncol Biol Phys. 2000 Feb 1; 46(3):609-17. PMID: 10701740.
      View in: PubMed
    119. Moore IK, Martin MP, Dorsey MJ, Paquin CE. Formation of circular amplifications in Saccharomyces cerevisiae by a breakage-fusion-bridge mechanism. Environ Mol Mutagen. 2000; 36(2):113-20. PMID: 11013409.
      View in: PubMed
    120. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000 Jan; 11(1):69-72. PMID: 10690390.
      View in: PubMed
    121. López-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodríguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol. 2000; 11 Suppl 1:137-40. PMID: 10707796.
      View in: PubMed
    122. Zheng N, Monckton DG, Wilson G, Hagemeister F, Chakraborty R, Connor TH, Siciliano MJ, Meistrich ML. Frequency of minisatellite repeat number changes at the MS205 locus in human sperm before and after cancer chemotherapy. Environ Mol Mutagen. 2000; 36(2):134-45. PMID: 11013412.
      View in: PubMed
    123. Donato ML, Champlin RE, Van Besien KW, Korbling M, Cabanillas F, Anderlini P, Gajewski JG, Lauppe J, Durett A, Andersson B, Giralt S, Khouri I, Hagemeister F, Romaguera JE, Sarris A, McLaughlin P, Younes A, Ippoliti C, Blamble DA, Hester J, Gee A, Rodriguez MA. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Oct; 35(3-4):317-24. PMID: 10706456.
      View in: PubMed
    124. McLaughlin P, Hagemeister FB, Grillo-López AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol. 1999 Oct; 26(5 Suppl 14):79-87. PMID: 10561022.
      View in: PubMed
    125. Hagemeister FB. The role of ifosfamide in the treatment of lymphomas. Leuk Lymphoma. 1999 Aug; 34(5-6):433-41. PMID: 10492066.
      View in: PubMed
    126. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999 Aug; 17(8):2461-70. PMID: 10561310.
      View in: PubMed
    127. Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999 Jul 20; 131(2):88-95. PMID: 10419446.
      View in: PubMed
    128. Rodriguez J, Rodriguez MA, Fayad L, McLaughlin P, Swan F, Sarris A, Romaguera J, Andersson B, Cabanillas F, Hagemeister FB. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood. 1999 Jun 1; 93(11):3632-6. PMID: 10339468.
      View in: PubMed
    129. Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Körbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32. PMID: 10416001.
      View in: PubMed
    130. López-Guillermo A, Cabanillas F, McDonnell TI, McLaughlin P, Smith T, Pugh W, Hagemeister F, Rodríguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Lee MS. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood. 1999 May 1; 93(9):3081-7. PMID: 10216105.
      View in: PubMed
    131. Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, Pugh W, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Witzig T, Duvic M, Andreeff M, Cabanillas F. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol. 1999 Apr; 10(4):433-40. PMID: 10370786.
      View in: PubMed
    132. Rodriguez J, McLaughlin P, Hagemeister FB, Fayad L, Rodriguez MA, Santiago M, Hess M, Romaguera J, Cabanillas F. Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood. 1999 Apr 1; 93(7):2202-7. PMID: 10090928.
      View in: PubMed
    133. Ha CS, Kavadi V, Dimopoulos MA, Hagemeister FB, Osborne BM, Fuller LM, Smith TL, Hess MA, McLaughlin PW, Cabanillas FF, Cox JD. Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria. Int J Radiat Oncol Biol Phys. 1999 Jan 15; 43(2):329-34. PMID: 10030257.
      View in: PubMed
    134. Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Rodriguez J, Preti A, Younes A, Sarris AH, Cabanillas F. Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. Invest New Drugs. 1999; 17(2):187-92. PMID: 10638491.
      View in: PubMed
    135. Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998 Dec; 16(12):3803-9. PMID: 9850025.
      View in: PubMed
    136. Younes A, Romaguera J, Mesina O, Hagemeister F, Sarris AH, Rodriguez MA, McLaughlin P, Preti HA, Bachier C, Cabanillas F. Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. Br J Haematol. 1998 Dec; 103(3):678-83. PMID: 9858216.
      View in: PubMed
    137. Romaguera JE, Hagemeister FB, McLaughlin P, Rodriguez MA, Bachier C, Preti H, Sarris AH, Weber D, Younes A, Cabanillas F. Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma. 1998 Dec; 32(1-2):97-106. PMID: 10037005.
      View in: PubMed
    138. Vlachaki MT, Ha CS, Hagemeister FB, Fuller LM, Rodriguez MA, Hess MA, Tucker SL, Cabanillas F, Cox JD. Stage I Hodgkin disease: radiation therapy and chemotherapy at the University of Texas M. D. Anderson Cancer Center, 1996-1997. Radiology. 1998 Sep; 208(3):739-47. PMID: 9722855.
      View in: PubMed
    139. Liao Z, Ha CS, Fuller LM, Hagemeister FB, Cabanillas F, Tucker SL, Hess MA, Cox JD. Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors. Int J Radiat Oncol Biol Phys. 1998 Jul 15; 41(5):1047-56. PMID: 9719114.
      View in: PubMed
    140. Cabanillas F, Rodriguez-Diaz Pavón J, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera JE, Dong K, Moon T. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma. Ann Oncol. 1998 May; 9(5):511-8. PMID: 9653492.
      View in: PubMed
    141. López-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodríguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS. The clinical significance of molecular response in indolent follicular lymphomas. Blood. 1998 Apr 15; 91(8):2955-60. PMID: 9531606.
      View in: PubMed
    142. Bouvet M, Staerkel GA, Spitz FR, Curley SA, Charnsangavej C, Hagemeister FB, Janjan NA, Pisters PW, Evans DB. Primary pancreatic lymphoma. Surgery. 1998 Apr; 123(4):382-90. PMID: 9551063.
      View in: PubMed
    143. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998 Feb 15; 91(4):1178-84. PMID: 9454747.
      View in: PubMed
    144. Cather JC, Jackow C, Yegge J, Hagemeister F, Duvic M. Mycosis fungoides with focal segmental glomerular sclerosis and nephrotic syndrome. J Am Acad Dermatol. 1998 Feb; 38(2 Pt 2):301-5. PMID: 9486702.
      View in: PubMed
    145. Fuller LM, Mirza NQ, Palmer JL, Davis BR, Ha CS, Rodriguez MA, Hagemeister FB, Cabanillas F, McLaughlin P, Butler JJ, North LB, Martin RG. Hodgkin's disease: correlation of clinical characteristics with probabilities for negative lymphangiogram vs. negative laparotomy findings in patients with Stage I supradiaphragmatic presentations vs. those in patients with Stage II. Int J Radiat Oncol Biol Phys. 1998 Jan 15; 40(2):377-86. PMID: 9457824.
      View in: PubMed
    146. Romaguera JE, Rodríguez Díaz-Pavon J, Carías L, Hagemeister FB, McLaughlin P, Rodríguez MA, Sarris AH, Younes A, Preti A, Bachier C, Llerena E, Cabanillas F. Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patients. Leuk Lymphoma. 1998 Jan; 28(3-4):295-306. PMID: 9517501.
      View in: PubMed
    147. Meistrich ML, Wilson G, Mathur K, Fuller LM, Rodriguez MA, McLaughlin P, Romaguera JE, Cabanillas FF, Ha CS, Lipshultz LI, Hagemeister FB. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J Clin Oncol. 1997 Dec; 15(12):3488-95. PMID: 9396402.
      View in: PubMed
    148. Vlachaki MT, Ha CS, Hagemeister FB, Fuller LM, Rodriguez MA, Besa PC, Hess MA, Brown B, Cabanillas F, Cox JD. Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies. Int J Radiat Oncol Biol Phys. 1997 Oct 1; 39(3):609-16. PMID: 9336140.
      View in: PubMed
    149. Vlachaki MT, Hagemeister FB, Fuller LM, Besa PC, Hess MA, Brown B, Cabanillas F, Cox JD. Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression. Int J Radiat Oncol Biol Phys. 1997 Jun 1; 38(3):593-9. PMID: 9231684.
      View in: PubMed
    150. Younes A, Rodriguez MA, McLaughlin P, North L, Sarris AH, Pate O, Hagemeister FB, Romaguera J, Preti A, Bachier C, Cabanillas F. Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 1997 Jun; 26(1-2):77-82. PMID: 9250790.
      View in: PubMed
    151. Robbins WA, Meistrich ML, Moore D, Hagemeister FB, Weier HU, Cassel MJ, Wilson G, Eskenazi B, Wyrobek AJ. Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Nat Genet. 1997 May; 16(1):74-8. PMID: 9140398.
      View in: PubMed
    152. Younes A, Ayoub JP, Sarris A, Hagemeister F, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Kurzrock R, Preti A, Bachier C, Smith T, Cabanillas F. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol. 1997 Feb; 96(2):328-32. PMID: 9029021.
      View in: PubMed
    153. Younes A, Ayoub JP, Sarris A, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Hagemeister F, Bachier C, Preti A, Cabanillas F. Paclitaxel (Taxol) for the treatment of lymphoma. Ann Oncol. 1997; 8 Suppl 1:129-31. PMID: 9187446.
      View in: PubMed
    154. Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am J Med. 1997 Jan; 102(1):21-8. PMID: 9209197.
      View in: PubMed
    155. Younes A, Cabanillas F, McLaughlin PW, Hagemeister FB, Farber C, Sarris A, Pate O, Myers J, Portlock C. Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease. Ann Oncol. 1996 Dec; 7(10):1083-5. PMID: 9037370.
      View in: PubMed
    156. Fayad L, Robertson LE, O'Brien S, Manning JT, Wright S, Hagemeister F, Cabanillas F, Keating MJ. Hodgkin's disease variant of Richter's syndrome: experience at a single institution. Leuk Lymphoma. 1996 Oct; 23(3-4):333-7. PMID: 9031114.
      View in: PubMed
    157. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996 Apr; 14(4):1262-8. PMID: 8648382.
      View in: PubMed
    158. Hagemeister FB. Hodgkin's disease: the next decade. Leuk Lymphoma. 1996 Mar; 21(1-2):53-61. PMID: 8907270.
      View in: PubMed
    159. Younes A, Ayoub JP, Hagemeister FB, McLaughlin P, Sarris A, Rodriguez MA, Swan F, Romaguera JE, Martin J, Cabanillas F. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J Clin Oncol. 1996 Feb; 14(2):543-8. PMID: 8636769.
      View in: PubMed
    160. Seymour JF, McLaughlin P, Fuller LM, Hagemeister FB, Hess M, Swan F, Romaguera J, Rodriguez MA, Besa P, Cox J, Cabanillas F. High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. Ann Oncol. 1996 Feb; 7(2):157-63. PMID: 8777172.
      View in: PubMed
    161. Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Mansfield P, Callendar D, Mesina O, Cabanillas F. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1996 Jan; 14(1):233-9. PMID: 8558203.
      View in: PubMed
    162. Hagemeister FB. Treatment of small non-cleaved cell lymphoma in the adult. Biomed Pharmacother. 1996; 50(9):433-41. PMID: 8991114.
      View in: PubMed
    163. Hagemeister FB. Low-grade lymphomas: new entities and treatment concepts. Med Oncol. 1995 Sep; 12(3):131-42. PMID: 8852395.
      View in: PubMed
    164. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995 Jul; 13(7):1734-41. PMID: 7602363.
      View in: PubMed
    165. Rodriguez MA, Cabanillas FC, Hagemeister FB, McLaughlin P, Romaguera JE, Swan F, Velasquez W. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol. 1995 Jul; 6(6):609-11. PMID: 8573542.
      View in: PubMed
    166. Suki S, Swan F, Tucker S, Fritsche HA, Redman JR, Rodriguez MA, McLaughlin P, Romaguera J, Hagemeister FB, Velasquez WS, et al. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk Lymphoma. 1995 Jun; 18(1-2):87-92. PMID: 8580834.
      View in: PubMed
    167. Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K, Dimopoulos M, Giralt S, Khouri I, Samuels B, et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma. 1995 May; 17(5-6):427-33. PMID: 7549833.
      View in: PubMed
    168. Younes A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, Rodriguez MA, Hagemeister F, Moore D, North L, et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1995 Mar; 13(3):583-7. PMID: 7884419.
      View in: PubMed
    169. Moore DF, Swan F, Yau J, Rodriguez MA, McLaughlin P, Sarris A, Romaguera J, Younes A, Hagemeister FB, Cabanillas F. Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II study. Clin Oncol (R Coll Radiol). 1995; 7(5):300-3. PMID: 8580055.
      View in: PubMed
    170. Fuller LM, Krasin MJ, Velasquez WS, Allen PK, McLaughlin P, Rodriguez MA, Hagemeister FB, Swan F, Cabanillas F, Palmer JL, et al. Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int J Radiat Oncol Biol Phys. 1995 Jan 1; 31(1):3-11. PMID: 7527799.
      View in: PubMed
    171. Diaz-Pavon JR, Cabanillas F, Majlis A, Hagemeister FB. Outcome of Hodgkin's disease in elderly patients. Hematol Oncol. 1995 Jan-Feb; 13(1):19-27. PMID: 7750925.
      View in: PubMed
    172. Rodriguez J, Pugh WC, Romaguera JE, Luthra R, Hagemeister FB, McLaughlin P, Rodriguez MA, Swan F, Cabanillas F. Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase. Ann Oncol. 1994 Nov; 5(9):847-9. PMID: 7848887.
      View in: PubMed
    173. Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F. Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med. 1994 Nov 1; 121(9):633-40. PMID: 7944070.
      View in: PubMed
    174. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994 Jun; 12(6):1169-76. PMID: 8201379.
      View in: PubMed
    175. Velasquez WS, McLaughlin P, Fuller LM, Allen PK, Tucker SL, Swan F, Rodriguez MA, Hagemeister FB, Cabanillas FF. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis. Cancer. 1994 May 1; 73(9):2408-16. PMID: 7513251.
      View in: PubMed
    176. Hagemeister FB, Purugganan R, Fuller L, McLaughlin P, Swan F, Romaguera J, Rodriguez M, Cabanillas F. Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy. Semin Hematol. 1994 Apr; 31(2 Suppl 3):36-43. PMID: 8073308.
      View in: PubMed
    177. McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol. 1994 Mar; 12(3):575-9. PMID: 8120556.
      View in: PubMed
    178. Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Swan F, Moore DF, Sarris AH, Younes A, Hill D, Cabanillas F. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. Invest New Drugs. 1994; 12(3):217-22. PMID: 7896540.
      View in: PubMed
    179. Hagemeister FB, Purugganan R, Podoloff DA, Hess M, Rodriguez MA, McLaughlin P, Swan F, Romaguera JE, Cabanillas F. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann Oncol. 1994; 5 Suppl 2:59-63. PMID: 8204521.
      View in: PubMed
    180. McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Romaguera J, Rodriguez MA, Lee MS, Pate O, Sarris A, Younes A. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol. 1994; 5 Suppl 2:73-7. PMID: 7515650.
      View in: PubMed
    181. Hagemeister FB, Khetan R, Allen P, McLaughlin P, Rodriguez MA, Swan F, Romaguera JE, Cabanillas F. Stage, serum LDH, and performance status predict disease progression and survival in HIV-associated lymphomas. Ann Oncol. 1994; 5 Suppl 2:41-6. PMID: 8204519.
      View in: PubMed
    182. Preti A, Hagemeister FB, McLaughlin P, Swan F, Rodriguez A, Besa P, Cox JD, Allen PK, Cabanillas F. Hodgkin's disease with a mediastinal mass greater than 10 cm: results of four different treatment approaches. Ann Oncol. 1994; 5 Suppl 2:97-100. PMID: 7515653.
      View in: PubMed
    183. Dimopoulos MA, Cabanillas F, Lee JJ, Swan F, Fuller L, Allen PK, Hagemeister FB. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. J Clin Oncol. 1993 Jun; 11(6):1108-11. PMID: 8501496.
      View in: PubMed
    184. Robertson LE, Hall R, Keating MJ, Estey E, Kantarjian HM, McLaughlin P, Hagemeister FB, Plunkett W. High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis. Leuk Lymphoma. 1993 May; 10(1-2):43-8. PMID: 8374522.
      View in: PubMed
    185. Liang JC, Bailey NM, Gabriel GJ, Kattan MW, Wang RY, Hagemeister FB, Cabanillas FF, Fuller LM. A new chemotherapy regimen for treatment of Hodgkin's disease associated with minimal genotoxicity. Leuk Lymphoma. 1993 Apr; 9(6):503-8. PMID: 7687918.
      View in: PubMed
    186. McLaughlin P, Cabanillas F, Hagemeister FB, Swan F, Romaguera JE, Taylor S, Rodriguez MA, Velasquez WS, Redman JR, Gutterman JU. CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol. 1993 Mar; 4(3):205-11. PMID: 7682436.
      View in: PubMed
    187. Rodriguez MA, Fuller LM, Zimmerman SO, Allen PK, Brown BW, Munsell MF, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, et al. Hodgkin's disease: study of treatment intensities and incidences of second malignancies. Ann Oncol. 1993 Feb; 4(2):125-31. PMID: 8448080.
      View in: PubMed
    188. Hagemeister FB. Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology. Leuk Lymphoma. 1993; 10 Suppl:21-7. PMID: 7683228.
      View in: PubMed
    189. Hagemeister FB. Are alkylating agents a necessary component in the therapy of Hodgkin's disease. Leuk Lymphoma. 1993; 10 Suppl:91-7. PMID: 7683230.
      View in: PubMed
    190. Spinolo JA, Jagannath S, Velásquez W, Spitzer G, Cabanillas F, Hagemeister F, Horwitz LJ, Dicke KA. Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease. Leuk Lymphoma. 1993 Jan; 9(1-2):71-7. PMID: 8477204.
      View in: PubMed
    191. Rodríguez J, Cabanillas F, McLaughlin P, Swan F, Rodríguez M, Hagemeister F, Romaguera J. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol. 1992 Nov; 3(9):711-7. PMID: 1450060.
      View in: PubMed
    192. Hagemeister FB, Fuller L, McLaughlin P, Rodriguez M, Romaguera J, Swan F, Cabanillas F. NOVP and radiotherapy for early-staged Hodgkin's disease: an interim analysis. Ann Oncol. 1992 Sep; 3 Suppl 4:87-90. PMID: 1450086.
      View in: PubMed
    193. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F, Rodriguez MA, Plunkett WK, Keating MJ. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992 May; 10(5):790-4. PMID: 1373760.
      View in: PubMed
    194. Hagemeister FB. Academia is not scutwork free. Ann Intern Med. 1992 May 1; 116(9):779. PMID: 1558358.
      View in: PubMed
    195. Spinolo JA, Cabanillas F, Dixon DO, Khorana SM, McLaughlin P, Velasquez WS, Hagemeister FB, Redman JR, Swan F. Therapy of relapsed or refractory low-grade follicular lymphomas: factors associated with complete remission, survival and time to treatment failure. Ann Oncol. 1992 Mar; 3(3):227-32. PMID: 1586621.
      View in: PubMed
    196. Cabanillas F, Velasquez WS, Hagemeister FB, McLaughlin P, Redman JR. Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma. Blood. 1992 Feb 15; 79(4):1024-8. PMID: 1737086.
      View in: PubMed
    197. Woo SY, Fuller LM, Cundiff JH, Bondy ML, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Rodriguez MA, Cabanillas F, et al. Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease. Int J Radiat Oncol Biol Phys. 1992; 23(2):407-12. PMID: 1587764.
      View in: PubMed
    198. Bodey G, Reuben A, Elting L, Kantarjian H, Keating M, Hagemeister F, Koller C, Velasquez W, Papadopoulos N. Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever. Eur J Clin Microbiol Infect Dis. 1991 Jul; 10(7):551-8. PMID: 1915397.
      View in: PubMed
    199. Litam P, Swan F, Cabanillas F, Tucker SL, McLaughlin P, Hagemeister FB, Rodriguez MA, Velasquez WS. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med. 1991 May 15; 114(10):855-60. PMID: 2014946.
      View in: PubMed
    200. Romaguera JE, McLaughlin P, North L, Dixon D, Silvermintz KB, Garnsey LA, Velasquez WS, Hagemeister FB, Cabanillas F. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol. 1991 May; 9(5):762-9. PMID: 1707956.
      View in: PubMed
    201. Velasquez WS, Fuller LM, Jagannath S, Tucker SL, North LB, Hagemeister FB, McLaughlin P, Swan F, Redman JR, Rodriguez MA, et al. Stages I and II diffuse large cell lymphomas: prognostic factors and long-term results with CHOP-bleo and radiotherapy. Blood. 1991 Mar 1; 77(5):942-7. PMID: 1704805.
      View in: PubMed
    202. Robertson LE, Redman JR, Butler JJ, Osborne BM, Velasquez WS, McLaughlin P, Swan F, Rodriguez MA, Hagemeister FB, Fuller LM, et al. Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse. J Clin Oncol. 1991 Feb; 9(2):236-42. PMID: 1988571.
      View in: PubMed
    203. McLaughlin P, Fuller L, Redman J, Hagemeister F, Durr E, Allen P, Holmes L, Velasquez W, Swan F, Cabanillas F. Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy. Ann Oncol. 1991 Feb; 2 Suppl 2:137-40. PMID: 1710918.
      View in: PubMed
    204. Hagemeister FB, Fuller LM, Velasquez WS, McLaughlin P, Redman JR, Swan F, Rodriguez MA, North L, Dixon D, Silvermintz K, et al. Two cycles of MOPP and radiotherapy: effective treatment for stage IIIA and IIIB Hodgkin's disease. Ann Oncol. 1991 Jan; 2(1):25-31. PMID: 2009233.
      View in: PubMed
    205. Hagemeister FB, Cabanillas F, Velásquez WS, Meistrich ML, Liang JC, McLaughlin P, Redman JR, Romaguera JE, Rodríguez MA, Swan F, et al. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin Oncol. 1990 Dec; 17(6 Suppl 10):34-8; discussion 38-40. PMID: 2259922.
      View in: PubMed
    206. Romagurea JE, Velasquez WS, Silvermintz KB, Fuller LB, Hagemeister FB, McLaughlin P, Cabanillas F. Surgical debulking is associated with improved survival in stage I-II diffuse large cell lymphoma. Cancer. 1990 Jul 15; 66(2):267-72. PMID: 2369711.
      View in: PubMed
    207. Givens SS, Fuller LM, Hagemeister FB, Gehan EA. Treatment of lower torso stages I and II Hodgkin's disease with radiation with or without adjuvant mechlorethamine, vincristine, procarbazine, and prednisone. Cancer. 1990 Jul 1; 66(1):69-74. PMID: 2354411.
      View in: PubMed
    208. Lopez TM, Hagemeister FB, McLaughlin P, Velasquez WS, Swan F, Redman JR, Rodriguez MA, Tucker SL, Silvermintz K, Johnson J, et al. Small noncleaved cell lymphoma in adults: superior results for stages I-III disease. J Clin Oncol. 1990 Apr; 8(4):615-22. PMID: 2313330.
      View in: PubMed
    209. Hagemeister FB, Fesus SM, Lamki LM, Haynie TP. Role of the gallium scan in Hodgkin's disease. Cancer. 1990 Mar 1; 65(5):1090-6. PMID: 2302660.
      View in: PubMed
    210. Sen P, Bailey NM, Hagemeister FB, Liang JC. Induction of chromosome breaks and sister chromatid exchanges in patients with Hodgkin's disease by two combination chemotherapy regimens of different leukemogenic potential. Cancer Res. 1990 Feb 1; 50(3):558-62. PMID: 1688733.
      View in: PubMed
    211. Taylor KM, Jagannath S, Spitzer G, Spinolo JA, Tucker SL, Fogel B, Cabanillas FF, Hagemeister FB, Souza LM. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol. 1989 Dec; 7(12):1791-9. PMID: 2479719.
      View in: PubMed
    212. Swan F, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, Hagemeister FB, Cabanillas F. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. 1989 Oct; 7(10):1518-27. PMID: 2674337.
      View in: PubMed
    213. Fesus SM, Hagemeister FB, Manning J. Hodgkin disease in a patient with common variable immunodeficiency. Am J Hematol. 1989 Oct; 32(2):138-42. PMID: 2757010.
      View in: PubMed
    214. Velasquez WS, Jagannath S, Tucker SL, Fuller LM, North LB, Redman JR, Swan F, Hagemeister FB, McLaughlin P, Cabanillas F. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data. Blood. 1989 Aug 1; 74(2):551-7. PMID: 2752132.
      View in: PubMed
    215. Cabanillas F, Pathak S, Grant G, Hagemeister FB, McLaughlin P, Swan F, Rodriguez MA, Trujillo J, Cork A, Butler JJ, et al. Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma. Am J Med. 1989 Aug; 87(2):167-72. PMID: 2757057.
      View in: PubMed
    216. Fuller LM, Hagemeister FB, Velasquez WS, Sullivan MP. Hodgkin's disease and non-Hodgkin's lymphomas. Compr Ther. 1989 Aug; 15(8):3-11. PMID: 2670408.
      View in: PubMed
    217. Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, Vaughan WP, Kessinger A, Horwitz LJ, Hagemeister FB, et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1989 Feb; 7(2):179-85. PMID: 2644397.
      View in: PubMed
    218. Fuller LM, Hagemeister FB. Two cycles of MOPP and definitive radiotherapy for stage IIIA and IIIB Hodgkin's disease. Recent Results Cancer Res. 1989; 117:197-204. PMID: 2602645.
      View in: PubMed
    219. Spinolo JA, Jagannath S, Dicke KA, Smith KE, Cabanillas F, Hagemeister FB, Horwitz LJ, McLaughlin P, Swan F, Spitzer G. High-dose combination chemotherapy with cyclophosphamide, carmustine, etoposide, and autologous bone marrow transplantation in 60 patients with relapsed Hodgkin's disease: the M. D. Anderson experience. Recent Results Cancer Res. 1989; 117:233-8. PMID: 2602646.
      View in: PubMed
    220. McLaughlin P, Velasquez WS, Redman JR, Yung WK, Hagemeister FB, Rodriguez MA, Cabanillas F. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J Natl Cancer Inst. 1988 Nov 2; 80(17):1408-12. PMID: 3172268.
      View in: PubMed
    221. Cabanillas F, Pathak S, Trujillo J, Manning J, Katz R, McLaughlin P, Velasquez WS, Hagemeister FB, Goodacre A, Cork A, et al. Frequent nonrandom chromosome abnormalities in 27 patients with untreated large cell lymphoma and immunoblastic lymphoma. Cancer Res. 1988 Oct 1; 48(19):5557-64. PMID: 3416308.
      View in: PubMed
    222. van der Velden JW, van Putten WL, Guinee VF, Pfeiffer R, van Leeuwen FE, van der Linden EA, Vardomskaya I, Lane W, Durand M, Lagarde C, et al. Subsequent development of acute non-lymphocytic leukemia in patients treated for Hodgkin's disease. Int J Cancer. 1988 Aug 15; 42(2):252-5. PMID: 3403068.
      View in: PubMed
    223. Henkelmann GC, Hagemeister FB, Fuller LM. Two cycles of MOPP and radiotherapy for stage III1A and stage III1B Hodgkin's disease. J Clin Oncol. 1988 Aug; 6(8):1293-302. PMID: 3411342.
      View in: PubMed
    224. Hagemeister FB. Prognostic factors in decision-making in the clinical management of Hodgkin's disease. Hematol Oncol. 1988 Jul-Sep; 6(3):257-69. PMID: 3042583.
      View in: PubMed
    225. Cabanillas F, Pathak S, Trujillo J, Grant G, Cork A, Hagemeister FB, Velasquez WS, McLaughlin P, Redman J, Katz R, et al. Cytogenetic features of Hodgkin's disease suggest possible origin from a lymphocyte. Blood. 1988 Jun; 71(6):1615-7. PMID: 3370310.
      View in: PubMed
    226. Cabanillas F, Velasquez WS, McLaughlin P, Jagannath S, Hagemeister FB, Redman JR, Swan F, Rodriguez MA. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol. 1988 Apr; 25(2 Suppl 2):47-50. PMID: 3041599.
      View in: PubMed
    227. Fuller LM, Hagemeister FB, North LB, McLaughlin P, Velasquez WS, Cabanillas F. The adjuvant role of two cycles of MOPP and low-dose lung irradiation in stage IA through IIB Hodgkin's disease: preliminary results. Int J Radiat Oncol Biol Phys. 1988 Apr; 14(4):683-92. PMID: 3280532.
      View in: PubMed
    228. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 Jan; 71(1):117-22. PMID: 3334893.
      View in: PubMed
    229. Dixon DO, McLaughlin P, Hagemeister FB, Freireich EJ, Fuller LM, Cabanillas FF, Gehan EA. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol. 1987 Oct; 5(10):1670-2. PMID: 3655864.
      View in: PubMed
    230. North LB, Fuller LM, Sullivan-Halley JA, Hagemeister FB. Regression of mediastinal Hodgkin disease after therapy: evaluation of time interval. Radiology. 1987 Sep; 164(3):599-602. PMID: 3112862.
      View in: PubMed
    231. Lee MS, Blick MB, Pathak S, Trujillo JM, Butler JJ, Katz RL, McLaughlin P, Hagemeister FB, Velasquez WS, Goodacre A, et al. The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas. Blood. 1987 Jul; 70(1):90-5. PMID: 3297209.
      View in: PubMed
    232. McLaughlin P, Fuller LM, Velasquez WS, Butler JJ, Hagemeister FB, Sullivan-Halley JA, Dixon DO. Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol. 1987 Jun; 5(6):867-74. PMID: 3295130.
      View in: PubMed
    233. McLaughlin P, Cabanillas F, Hagemeister FB, Velasquez WS. Activity of bisantrene in refractory lymphoma. Cancer Treat Rep. 1987 Jun; 71(6):631-3. PMID: 3581102.
      View in: PubMed
    234. Hagemeister FB, Tannir N, McLaughlin P, Salvador P, Riggs S, Velasquez WS, Cabanillas F. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol. 1987 Apr; 5(4):556-61. PMID: 3559649.
      View in: PubMed
    235. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, Smith T. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol. 1987 Mar; 5(3):407-12. PMID: 3819806.
      View in: PubMed
    236. Newell GR, Cabanillas FG, Hagemeister FJ, Butler JJ. Incidence of lymphoma in the US classified by the working formulation. Cancer. 1987 Feb 15; 59(4):857-61. PMID: 3802044.
      View in: PubMed
    237. Kalter SP, Riggs SA, Cabanillas F, Butler JJ, Hagemeister FB, Mansell PW, Newell GR, Velasquez WS, Salvador P, Barlogie B, et al. Aggressive non-Hodgkin's lymphomas in immunocompromised homosexual males. Blood. 1985 Sep; 66(3):655-9. PMID: 4027383.
      View in: PubMed
    238. Pillai GN, Hagemeister FB, Velasquez WS, Sullivan JA, Johnston DA, Butler JJ, Shullenberger CC. Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin. Cancer. 1985 Feb 15; 55(4):691-7. PMID: 2578302.
      View in: PubMed
    239. da Cunha MF, Meistrich ML, Fuller LM, Cundiff JH, Hagemeister FB, Velasquez WS, McLaughlin P, Riggs SA, Cabanillas FF, Salvador PG. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. J Clin Oncol. 1984 Jun; 2(6):571-7. PMID: 6547167.
      View in: PubMed
    240. Dixon C, Hagemeister F, Legha S, Bodey G. Pulmonary toxicity associated with spirogermanium. Cancer Treat Rep. 1984 Jun; 68(6):907-8. PMID: 6733705.
      View in: PubMed
    241. Velasquez W, Fuller LM, Oh KK, Hagemeister FB, Sullivan JA, Manning JT, Shullenberger CC. Combined modality therapy in Stage III and Stage IIIE diffuse large cell lymphomas. Cancer. 1984 Apr 1; 53(7):1478-83. PMID: 6199100.
      View in: PubMed
    242. Perez-Soler R, McLaughlin P, Velasquez WS, Hagemeister FB, Zornoza J, Manning JT, Fuller LM, Cabanillas F. Clinical features and results of management of superior vena cava syndrome secondary to lymphoma. J Clin Oncol. 1984 Apr; 2(4):260-6. PMID: 6368759.
      View in: PubMed
    243. Tannir NM, Spitzer G, Zander AR, Jagannath S, Kanojia M, Vellekoop L, McLaughlin P, Hagemeister FJ, Dicke KA. High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma. Eur J Cancer Clin Oncol. 1983 Aug; 19(8):1091-6. PMID: 6352279.
      View in: PubMed
    244. Tannir N, Hagemeister F, Velasquez W, Cabanillas F. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol. 1983 Jul; 1(7):432-9. PMID: 6199478.
      View in: PubMed
    245. Fuller LM, Hagemeister FB. Diagnosis and management of Hodgkin's disease in the adult. Cancer. 1983 Jun 15; 51(12 Suppl):2469-76. PMID: 6687831.
      View in: PubMed
    246. Hagemeister FB, Fuller LM, Sullivan JA, Johnston D, North L, Butler JJ, Velasquez WS, Shullenberger CC. Treatment of patients with stages I and II nonmediastinal Hodgkin's disease. Cancer. 1982 Dec 1; 50(11):2307-13. PMID: 6754064.
      View in: PubMed
    247. Thomas JL, Bernardino ME, Vermess M, Barnes PA, Fuller LM, Hagemeister FB, Doppman J, Fisher RI, Longo DL. EOE-13 in the detection of hepatosplenic lymphoma. Radiology. 1982 Dec; 145(3):629-34. PMID: 6292995.
      View in: PubMed
    248. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood. 1982 Sep; 60(3):693-7. PMID: 7104493.
      View in: PubMed
    249. Hagemeister FB, Fuller LM, Velasquez WS, Sullivan JA, North L, Butler JJ, Johnston DA, Shullenberger CC. Stage I and II Hodgkin's disease: involved-field radiotherapy versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP. Cancer Treat Rep. 1982 Apr; 66(4):789-98. PMID: 7074649.
      View in: PubMed
    250. Thomas JL, Barnes PA, Bernardino ME, Hagemeister FB. Limited CT studies in monitoring treatment of lymphoma. AJR Am J Roentgenol. 1982 Mar; 138(3):537-9. PMID: 7039271.
      View in: PubMed
    251. North LB, Fuller LM, Hagemeister FB, Rodgers RW, Butler JJ, Shullenberger CC. Importance of initial mediastinal adenopathy in Hodgkin disease. AJR Am J Roentgenol. 1982 Feb; 138(2):229-35. PMID: 6976723.
      View in: PubMed
    252. Hagemeister FB, Fuller LM, Sullivan JA, North L, Velasquez W, Conrad FG, McLaughlin P, Butler JJ, Shullenberger CC. Treatment of stage I and II mediastinal Hodgkin disease. A comparison of involved fields, extended fields, and involved fields followed by MOPP in patients staged by laparotomy. Radiology. 1981 Dec; 141(3):783-9. PMID: 6895415.
      View in: PubMed
    253. Osborne BM, Hagemeister FB, Butler JJ. Extranodal gastrointestinal sinus histiocytosis with massive lymphadenopathy. Clinically presenting as a malignant tumor. Am J Surg Pathol. 1981 Sep; 5(6):603-11. PMID: 7325277.
      View in: PubMed
    254. Rodgers RW, Fuller LM, Hagemeister FB, Johnston DA, Sullivan JA, North LB, Butler JJ, Velasquez WS, Conrad FG, Shullenberger CC. Reassessment of prognostic factors in stage IIIA and IIIB Hodgkin's disease treated with MOPP and radiotherapy. Cancer. 1981 May 1; 47(9):2196-203. PMID: 7226112.
      View in: PubMed
    255. Hagemeister FB, Buzdar AU, Luna MA, Blumenschein GR. Causes of death in breast cancer: a clinicopathologic study. Cancer. 1980 Jul 1; 46(1):162-7. PMID: 7388758.
      View in: PubMed
    256. Fuller LM, Madoc-Jones H, Hagemeister FB, Rodgers RW, North LB, Butler JJ, Martin RG, Gamble JF, Shullenberger CC. Further follow-up of results of treatment in 90 laparotomy-negative stage I and II Hodgkin's disease patients: significance of mediastinal and non-mediastinal presentations. Int J Radiat Oncol Biol Phys. 1980 Jul; 6(7):799-808. PMID: 7204116.
      View in: PubMed
    257. Liposomal tretinoin. Blood. 96.
    258. Allogeneic hematopoietic transplantation for indolent lymphomas. Blood. 96.
    259. Diffuse undifferentiated lymphoma (DUL). 780.
    260. Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma. Ophthalmic Plastic and Reconstructive Surgery.
    261. Erratum. Cancer. 97:3131.
    262. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma. The Lancet Oncology. 15:69-77.
    263. Mitoxantrone as monotherapy versus combination therapy. Seminars in Oncology. 17:41-43.
    264. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Annals of Oncology. 27:895-901.
    265. Merkel cell carcinoma. Cancer Bulletin. 47:175-177.
    266. New approaches to management of stage IV Hodgkin's disease. Cancer Bulletin. 35:230-232.
    267. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. British Journal of Haematology.
    268. New approaches to management of Hodgkin's disease designed to minimize long-term sequelae. Cancer Bulletin. 41:88-93.
    269. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. British Journal of Haematology.
    270. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. British Journal of Haematology.
    271. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. British Journal of Haematology.
    272. Prognostic factors for stage IV Hodgkin's disease (HD) treated with MOPP.
    273. Treatment options for stage III Hodgkin's disease. Cancer Bulletin. 35:224-229.
    274. Controversies in the management of early stage Hodgkin's disease. Cancer Research Therapy and Control. 7:259-265.
    275. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. British Journal of Haematology.
    276. Hodgkin's lymphoma in the elderly. Oncology. 21.
    277. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma. British Journal of Haematology.
    278. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology. 171:726-735.
    279. Treatment of non-Hodgkin's lymphoma (NHL) with cytosine arabinoside arabinoside (ARA-C) and 6-thioguanine (6-TG). 967.
    280. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica. 100:e454-e457.
    281. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma. Clinical Lymphoma, Myeloma and Leukemia. 16:122-128.
    282. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation. 21:1914-1920.
    283. The FLIPI and the R-FLIPI. American Journal of Hematology/ Oncology. 6:364-368.
    284. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma. British Journal of Haematology. 175:290-299.
    285. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Annals of Oncology. 27:1317-1323.
    286. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica. 100:e272-e274.
    287. Hodgkin's disease stage I and II. Management considerations and results in adults. Cancer Bulletin. 35:218-223.
    288. Factors predicting for complete remission (CR) in patients (PTS) with recurrent lymphoma treated with salvage combination chemotherapy.
    289. Burkitt's lymphoma. Cancer Bulletin. 33:295-297.
    290. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma. The Lancet Oncology.
    291. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation.
    HAGEMEISTER's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description